NOW RECRUITING | Central Mechanisms and Treatment Response of Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor
This study aims to determine the central mechanisms underlying symptom improvement following the use of sodium oxybate (Xyrem), a possible novel oral medication for the treatment of spasmodic dysphonia and/or voice tremor. You are invited to participate in this study if you have spasmodic dysphonia with or without voice tremor. This study includes the intake of the investigational drug (sodium oxybate) and MRI of the brain before and after drug administration. The study is conducted at Massachusetts Eye and Ear and the Martinos Center for Biomedical Imaging. The study will include an MRI scan of your brain and a blood draw for genetic testing. Funding for this study is provided by the National Institute on Deafness and Other Communications Disorders (NIDCD), National Institutes of Health (NIH), R01DC012545 grant. All research procedures have been reviewed and approved by the Institutional Review Board (IRB) of Massachusetts Eye and Ear Infirmary, Human Subject Committee.
To obtain detailed information about the study and your eligibility for participation, please contact us by phone (617) 573-6016 or e-mail Simonyan_Lab@meei.harvard.edu. The preliminary screening will take approximately 20 minutes of your time. If you are eligible for the study participation, we will schedule your visit with our research team at your convenience. Upon the study completion, your out-of-town and/or local travel expenses associated with the study participation will be reimbursed and you will receive up to $200 compensation for your time and effort.